CTR20261803 Savolitinib c-Met positive Stomach Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines CTR20261803 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 22 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why CTR20261803 is a hot trial to watch
c-Met positive Stomach Cancer is being segmented by mechanism, treatment setting, geography and endpoint architecture. CTR20261803 is notable because it evaluates Savolitinib in a Phase 3 design sponsored by Hutchison MediPharma Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | CTR20261803 |
| Official title | 评价赛沃替尼对比紫杉醇治疗伴MET基因扩增的晚期胃癌和胃食道连接部腺癌的III期研究 |
| Phase / status | Phase 3 / 进行中 （招募中） |
| Intervention | Savolitinib |
| Sponsor | Hutchison MediPharma Ltd. |
| Geography | China |
| Enrollment | [object Object] |
| Primary endpoint | |
| Endpoint time frame | 整个试验期间 |
| Primary completion / readout proxy | Not reported |
Protocol design and endpoint interpretation
The indexed record describes a Phase 3 study of Savolitinib in c-Met positive Stomach Cancer.
Allocation is 随机化, masking is 开放, and the intervention model is 交叉设计. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary endpoint (整个试验期间) — 终点：独立阅片委员会（IRC）根据实体瘤疗效评价标准（RECIST）1.1版本评估的无进展生存期（PFS）。PFS定义为从随机化至PD或死亡的时间，以先发生者为准。
Readout outlook and evidence gap
The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Savolitinib is indexed as Small molecule drug, with target c-Met, mechanism c-Met inhibitors, and global highest development status Approved.
Company & Deal Intelligence MCP profile: Hutchison MediPharma Ltd. did not return an exact normalized organization match in this snapshot. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
CTR20261803 provides a focused lens on c-Met positive Stomach Cancer development. Its value will be determined by whether Savolitinib can convert the current Phase 3 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
